Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
Bio Medica Laboratories Ltd IPO
Bio Medica Laboratories Ltd
₹2,64,000 /2000 sharesMinimum investment
IPO details
Minimum investment
₹2,64,000
Price range
₹132 - ₹139
Lot size
1,000
Issue size
52.43 Cr
Face value
10
IPO document
Subscription rate
Data will be available soon
Schedule
21 May 2026
IPO open date
25 May 2026
IPO close date
26 May 2026
Allotment date
26 May 2026
Funds unblock or debit
28 May 2026
Tentative listing date
About
Founded in
2015
MD/CEO
Mr. Pradeep Mehta
Parent organisation
Bio Medica Laboratories Ltd
Bio Medica Laboratories Financials
Revenue
Total Assets
Profit
All values are in ₹ Cr
Strengths & Risks
Strengths
Risks
The company is led by promoters Mr. Pradeep Mehta and Mr. Mukesh Mehta, who collectively have over 37 years of experience in the pharmaceutical industry. This leadership has been instrumental in guiding the company's growth and operations since its incorporation.
BMLL manufactures 71 types of formulations, spanning generic drugs, branded pharmaceuticals, and over-the-counter (OTC) products. These are produced in both single-dose and multi-dose forms, catering to human and veterinary needs, allowing the company to serve multiple market segments through a single manufacturing setup.
The company holds GMP and GLP certificates issued by the Food and Drug Administration, Madhya Pradesh. It claims to maintain an in-house quality control team that conducts testing of both raw materials and finished goods throughout the manufacturing process.
The company claims to operate an in-house laboratory equipped with instruments, including HPLC, gas chromatography, UV-Vis spectrophotometer, and a polarimeter, among others. These are used for physical testing, process controls, and stability studies.
The company's employee attrition rate reduced from 14.12% in FY23 and has continued to decline through FY24 and FY25. This indicates a degree of workforce stability, which is operationally relevant for a manufacturing business dependent on trained personnel.
The company has reported consistent growth in profit after tax (PAT) over the last three financial years. PAT increased from Rs 0.33 crore in FY23 to Rs 2.50 crore in FY24 and Rs 9.79 crore in FY25.
The operations at the company's manufacturing unit-1 in Indore were suspended by the Deputy Director and State Licensing Authority, Food and Drug Administration, Madhya Pradesh, citing non-compliances under Rule 85(2) of the Drugs and Cosmetics Rules, 1945. As a result, the company is legally prohibited from carrying out production activities at this facility. If the licence is ultimately cancelled, the company would be required to undergo a time-consuming re-application process, further disrupting operations and impacting business performance. Following the suspension of manufacturing unit 1, the company is now reliant on manufacturing unit 2 to fulfil all customer demand. This concentration of production in a single operational facility increases the risk of supply disruption and may lead to increased operational costs, production schedule adjustments, and an inability to scale output in line with demand.
The top five customers contributed Rs 19.29 crore (67.58%), Rs 23.73 crore (62.13%), Rs 4.75 crore (31.15%), and Rs 5.58 crore (34.38%) to revenue from operations for FY25, FY24, and FY23, respectively. Any failure to retain these key customers or a loss of business from them can adversely affect the company's business and financial standing.
Both its manufacturing units are located in the Industrial Area, Sanwer Road, Indore, Madhya Pradesh. Any adverse political, social, economic, or regulatory developments in this region, including power supply disruptions, industrial disputes, or compliance-related directives from local authorities, could negatively impact the company's production and overall business operations.
The company recorded negative cash flows from operating activities amounting to Rs 5.76 crore and Rs 3.67 crore for the period ended November 30, 2025, and FY25, respectively. This is due to an increase in inventories, trade receivables, other current assets, and short-term loans and advances. Also, the cash flow position has been worsening over the years. This could put pressure on the bottom line. If cash outflows continue to exceed inflows, the company may face liquidity challenges in the future.
The company's promoters and directors are involved in certain legal proceedings currently pending before income tax authorities at different levels of adjudication. Any adverse decisions in any of these proceedings could have a material adverse effect on the company's business, results of operations, and financial condition.
As of November 30, 2025, the company has outstanding unsecured loans amounting to Rs 11.47 crore, which may be recalled by lenders at any time. In the event of such a recall, the company would need to arrange alternative financing, which may not be available on commercially reasonable terms, potentially impacting its operations and financial condition
Application details
For Bio Medica Laboratories IPO, eligible investors can apply as Individual investor.
| Apply as | Price band | Apply range | Lot size |
|---|---|---|---|
| Individual investor | ₹132 - ₹139 | ₹2 - ₹5 Lakhs | 1000 |